Thomas McCormack, MD
Psychiatry · Bogart, GANPI 1740298728
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,253 of the $161,791 with a category attached, or 72.5%. 35 manufacturers reported payments, led by AbbVie at 43.6% of the total. Reporting peaked in 2019 at $47,189 and has fallen 54.7% since, to $21,356 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,021 payments — averaging $158.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$71K
- Supernus Pharmaceuticals, Inc.$41K
- Axsome Therapeutics, Inc.$20K
- Ironshore Pharmaceuticals Inc.$14K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $9K from 29 others
What the payments were for
- Consulting fees$4,5003%
- Speaking & faculty fees$117,25372%
- Travel & lodging$22,68814%
- Food & beverage$16,97810%
- Education$3720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$68,511
- QELBREE$38,892
- Auvelity$19,618
- Jornay PM 20mg capsules (Bottle of 100)$12,108
- VYVANSE$5,342
How this compares
$161,791 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 78 | $130,983 |
| CaplytaLumateperone Tosylate | 51 | $109,240 |
| VraylarCariprazine Hcl | 64 | $102,311 |
| Invega SustennaPaliperidone Palmitate | 18 | $60,822 |
| FanaptIloperidone | 27 | $59,731 |
| AuvelityDextromethorphan Hbr/Bupropion | 45 | $55,464 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $31,731 |
| TrintellixVortioxetine Hydrobromide | 42 | $24,622 |
| VyvanseLisdexamfetamine Dimesylate | 47 | $21,553 |
| Lisdexamfetamine Dimesylate | 77 | $17,288 |
| Lurasidone Hcl | 69 | $16,315 |
| ProzacFluoxetine Hcl | 16 | $13,469 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 293 | $12,935 |
| QuviviqDaridorexant Hcl | 23 | $11,201 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 303 | $8,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $624 | $130,98378 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,246 | $109,24051 claims |
| AbbVieVraylar | $70,570 | $102,31164 claims |
| Johnson & JohnsonInvega Sustenna | $1,003 | $60,82218 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $891 | $59,73127 claims |
| Axsome Therapeutics, Inc.Auvelity | $19,913 | $55,46445 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $6,167 | $46,17589 claims |
| Alkermes, Inc.Lybalvi | $1,097 | $31,73120 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $145 | $11,20123 claims |
| Eisai Inc.Dayvigo | $115 | $5,40216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Bogart
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Jose CangianoAthens$244K
- Michael BurkeAtlanta$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.